

Contains Exact Match Begins With
 Name Code Property Relationship

[Advanced Search](#)

Version: 18.04e (Release date: 2018-04-30)

[Hierarchy](#) | [Value Sets](#) | [Maps](#) | [Visited Concepts](#) [Help](#)

[View in Hierarchy](#) | [View History](#) | [View Graph](#) | [Add to Cart](#) | [Suggest Changes](#)

Margetuximab (Code C91733)

Table of Contents

- [Terms & Properties](#)
- [Synonym Details](#)
- [Relationships](#)
- [Mapping Details](#)

Terms & Properties

Preferred Name: Margetuximab

Definition: A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcγ receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcγ receptor IIB (CD32B).

Display Name: Margetuximab

Label: Margetuximab

NCI Thesaurus Code: C91733 ([Search for linked caDSR metadata](#)) ([search value sets](#))

NCI Metathesaurus Link: CL421637 ([see NCI Metathesaurus info](#))

Synonyms & Abbreviations: ([see Synonym Details](#))

Immunoglobulin G1, Anti-(human Neu (Receptor)) (Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Heavy Chain), Disulfide with Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Light Chain, Dimer

Margetuximab
 MARGETUXIMAB
 MGAH-22
 MGAH22

External Source Codes:

FDA UNII Code	K911R84KEW
PDQ Closed Trial Search ID	681010
PDQ Open Trial Search ID	681010 (check for NCI PDQ open clinical trial info)
NCI META CUI	CL421637

Other Properties:

Name	Value (qualifiers indented underneath)
code	C91733
Contributing_Source	CTRP
Contributing_Source	FDA
Semantic_Type	Amino Acid, Peptide, or Protein
Semantic_Type	Pharmacologic Substance

Additional Concept Data:

Defined Fully by Roles: No

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91733

Synonym Details

Term	Source <input type="button" value="2"/>	Type <input type="button" value="2"/>	Code
Immunoglobulin G1, Anti-(human Neu (Receptor)) (Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Heavy Chain), Disulfide with Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Light Chain, Dimer	NCI	SN	
MARGETUXIMAB	FDA	PT	K911R84KEW
Margetuximab	NCI	PT	

MGAH-22 NCI CN
 MGAH22 NCI CN

Relationships with other NCI Thesaurus Concepts

Parent Concepts:

[Monoclonal Antibody](#)

Child Concepts: *(none)*

Role Relationships, asserted or inherited, pointing from the current concept to other concepts:
(True for the current concept and its descendants, may be inherited from parent(s).)

Relationship	Value (qualifiers indented underneath)
Biological Process	
Chemical_Or_Drug_Has_Mechanism_Of_Action	Antigen Binding

Associations pointing from the current concept to other concepts:
(True for the current concept.)

Relationship	Value (qualifiers indented underneath)
Concept_In_Subset	CTRP Agent Terminology
Concept_In_Subset	CTRP Terminology
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Concept_In_Subset	NCIt Antineoplastic Agent Terminology

Incoming Role Relationships, asserted or inherited, pointing from other concepts to the current concept: *(none)*

Incoming Associations pointing from other concepts to the current concept: *(none)*

Mapping relationships:

[see Mappings](#)

[Mapping Details](#)

Maps To:

Maps From:

Mapping Source: PDQ_2016_07_31_TO_NCI_2016_10E

Source	Source Code	Source Name	REL	Target	Target Code	Target Name
PDQ	CDR0000681010	margetuximab	SY	NCI	C91733	Margetuximab